The World Health Organization is a specialized agency of the United Nations. It was founded in 1948 to strengthen people's health worldwide, preserve peace, and provide assistance to vulnerable populations. The Center has experience of long-term and successful cooperation with WHO on many programs/projects:
WHO Prequalification Program for medicinal products
WHO Prequalification Programme, (WHO PQ)
The program helps ensure accelerated access to priority medical products, including medicinal products and vaccines. Medical products that have passed WHO prequalification meet acceptable standards of quality, safety, and efficacy.
Since 2013, the State Expert Center of the Ministry of Health of Ukraine has been a signatory to the Agreement on participation in the collaborative procedure between the World Health Organization (WHO) and the national regulatory authority (NRA), to which the Center belongs, on the assessment and accelerated national registration of medicinal products and vaccines that have passed the WHO prequalification procedure.
The use of the Collaborative Registration Procedure (CRP) for medicinal products and vaccines prequalified by WHO, as well as for medicinal products approved by authorities included in the WHO List (formerly stringent regulatory authorities – SRAs), serves to accelerate expert evaluation for registration, relying on the shared confidential reports of regulatory coordination centers at the request of manufacturers.
Since the introduction of the WHO collaborative procedure for medicinal products, the Center's specialists have joined meetings of coordinators who carry out the procedures in national authorities almost every year.
Participation in them provides an opportunity to master the best practices of the world's regulators in implementing joint registrations (assessments and inspections) and effective management of post-approval changes in order to support accelerated national registration of prequalified medicinal products, vaccines, and medical devices, including for in-vitro diagnostics.
Read more information here
WHO Program for International Monitoring of Medicinal Products
The WHO Programme for International Drug Monitoring (PIDM)
The WHO Program for International Drug Monitoring (PIDM) is a global collaboration for the development of pharmacovigilance in countries around the world. The WHO PIDM was established in 1968 at the Uppsala Monitoring Center (Sweden) in order to ensure the collection of data on harm caused by the use of medicinal products from as many sources as possible.
Participation in the program gives the Center the opportunity to be aware of current global data on the safety of medicinal products/vaccines that may not be apparent from local data alone.
Ukraine as a full member of PIDM since 2002.
The Center submits monthly to the WHO global database VigiBase reports of adverse reactions associated with medicinal products/vaccines and receives information on medicinal product safety signals. The information is analyzed and implemented in Ukraine by providing recommendations to the applicant on updating the safety information in the instructions for medical use. If necessary, the Center may receive safety information on individual active substances/medicinal products. The data are used as additional information when analyzing the safety information of medicinal products on the territory of Ukraine.
Also, as part of cooperation under the program, the Center's specialists regularly take part in training sessions on medicine/vaccine safety issues.
Read more information here
WHO Global Vaccine Safety Initiative
Global Vaccine Safety Initiative (GVSI)
The WHO Global Vaccine Safety Initiative was established in 2012. The goal is to build effective vaccine pharmacovigilance systems in all countries of the world and to improve monitoring and response to vaccine safety issues.
The Center has cooperated with GVSI since 2015 in implementing current vaccine safety recommendations, obtaining up-to-date safety information, current data on vaccination of specific population groups, vaccination schedules, approaches to establishing criteria when determining a causal relationship, etc.
Read more information here
WHO Collaborating Center for Methodology of Statistical Studies
WHO Collaborating Centre for Drug Statistics Methodology The WHO Collaborating Centre for Drug Statistics Methodology was established in 1982. Its main tasks are to develop and maintain the international Anatomical Therapeutic Chemical (ATC) classification system of medicinal products and to establish Defined Daily Doses (DDD) for medicinal products.
The Center has used the ATC/DDD classification system since 2010. During the specialized expert evaluation of instructions for medical use of a medicinal product, the conformity of the ATC code of the medicinal product with the WHO international classifier (
http://www.whocc.no/atc_ddd_index/) is established. A change of the ATC code is provided for by the Procedure for conducting expert evaluation of registration materials for medicinal products submitted for state registration (re-registration), as well as expert evaluation of materials on amendments to registration materials during the validity of the registration certificate (MoH Order No. 426, as amended), and takes place upon assignment of a new ATC code or a change of the ATC code in accordance with a WHO decision. The ATC code of a medicinal product is used to collect statistical data and to compile registers and lists of medicinal products.
Global Benchmarking Tool (GBT) for assessing national regulatory systems
WHO Global Benchmarking Tool (GBT) for evaluation of national regulatory systems
WHO began assessing regulatory systems in 1997, using a set of indicators developed to assess the vaccine regulatory program. In 2014, work began on developing a unified tool for assessing medicines regulatory programs. Today, the Global Benchmarking Tool (GBT) is the main means by which WHO objectively assesses regulatory systems, as provided for by WHO Resolution 67.20 “Strengthening regulatory systems for medical devices”.
Assessment of the national regulatory system (benchmarking)
Since 2021, the Ministry of Health of Ukraine, jointly with the World Health Organization (hereinafter – WHO), has been conducting a comparative analysis of the current regulatory system in the field of medicinal product circulation in order to obtain an objective assessment of the national regulatory system. At present, in addition to the MoH of Ukraine, the State Expert Center of the Ministry of Health of Ukraine and the State Service of Ukraine on Medicinal Products and Drugs Control participate in this process.
The review and assessment are carried out in the following areas:
- national regulatory system (RS);
- marketing authorization and registration (MA);
- post-licensing product surveillance (VL);
- market surveillance and control (MC);
- authorization/license-granting institutions and regulatory inspection (LI and RI);
- oversight of clinical trials (CT);
- laboratory testing (LT) and national batch release (LR).
In July 2023, a preliminary comparative analysis of Ukraine's regulatory system – pre-benchmarking – took place. The assessment is scheduled to be completed in 2024.
Read more information here